<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; OMCL</title>
	<atom:link href="http://www.stockbloghub.com/tag/omcl/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(OMCL) Omnicell Analyst Reaffirms Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/12/14/omcl-omnicell-analyst-reaffirms-shares-at-neutral/87973</link>
		<comments>http://www.stockbloghub.com/2011/12/14/omcl-omnicell-analyst-reaffirms-shares-at-neutral/87973#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:11:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87973</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Omnicell (OMCL) with a target price of $17.00. Omnicell reported adjusted EPS of 9 cents in the third quarter of fiscal 2011, beating the Zacks Consensus Estimate by a penny and the year-ago quarter EPS of 4 cents. Revenues in the reported quarter increased 5.6% year over year to $64.4 million and surpassed the Zacks Consensus Estimate of $63 million. The company primarily operates in the niche automated medication distribution industry and stands to benefit from favorable demographic trends, regulatory environments, and the lack of nursing staff. As the information technology market is growing in leaps and bounds with increasing investment by healthcare industries and gradual modernization of the healthcare system, the demand for automated healthcare management systems has also been on the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/14/omcl-omnicell-analyst-reaffirms-shares-at-neutral/87973/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell&#8217;s G4 Platform Reaches China</title>
		<link>http://www.stockbloghub.com/2011/11/30/omcl-omnicells-g4-platform-reaches-china/87704</link>
		<comments>http://www.stockbloghub.com/2011/11/30/omcl-omnicells-g4-platform-reaches-china/87704#comments</comments>
		<pubDate>Wed, 30 Nov 2011 19:57:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[Gartner Inc.]]></category>
		<category><![CDATA[IT]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87704</guid>
		<description><![CDATA[Recently, Omnicell (OMCL) announced the launch of Mandarin-language versions of its G4 platform for clinical use in China. Following the launch of G4 medication automation platform in English-speaking markets earlier this year, the language conversion of medication cabinets will enable Chinese hospitals to utilize all the advanced operational improvements of G4. The latest move on the company’s part is consistent with its strategy of further expanding in the international market. In China, this system was first implemented at Peking Union Medical College Hospital (PUMCH). A recently completed multi-month pilot study at PUMCH showed that the Omnicell ADCs on Mandarin-language conserve workforce for locating medications by nearly two hours per day. Additionally, Omnicell announced a partnership with China Resources Beijing Pharmaceutical Co. Ltd., which is a subsidiary of China Resources Pharmaceutical ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/omcl-omnicells-g4-platform-reaches-china/87704/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell Beats Estimates</title>
		<link>http://www.stockbloghub.com/2011/11/04/omcl-omnicell-beats-estimates/86102</link>
		<comments>http://www.stockbloghub.com/2011/11/04/omcl-omnicell-beats-estimates/86102#comments</comments>
		<pubDate>Fri, 04 Nov 2011 18:57:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86102</guid>
		<description><![CDATA[Omnicell Inc. (OMCL) reported EPS of 9 cents during the second quarter of fiscal 2011, beating both the Zacks Consensus Estimate of 8 cents and the year-ago quarter EPS of 4 cents. Reported earnings shot up 125% on a year-over-year basis primarily due to the reduction in effective tax rate from 60% in the year-ago quarter to 35% in the reported quarter. Revenues in the reported quarter increased 5.6% year over year to $64.4 million and surpassed the Zacks Consensus Estimate of $63 million. Product revenue, contributing 77.3% of revenues, increased 15.0% to $49.7 million in the quarter while the same from Services and Others (contributing the rest), witnessed an upside of 12.3%. Cost of Product sales were up 13.6% to $22.4 million in the quarter. However, cost of Services ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/04/omcl-omnicell-beats-estimates/86102/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/09/20/omcl-omnicell-analyst-maintains-neutral-on-shares/83310</link>
		<comments>http://www.stockbloghub.com/2011/09/20/omcl-omnicell-analyst-maintains-neutral-on-shares/83310#comments</comments>
		<pubDate>Tue, 20 Sep 2011 20:17:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83310</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Omnicell (OMCL) with a target price of $16.00. Omnicell reported an adjusted EPS of 8 cents in the second quarter of fiscal 2011, beating both the Zacks Consensus Estimate and the year-ago quarter’s EPS of 6 cents. Total revenue for the second quarter was $61.0 million, up 6.6% year over year and surpassed the Zacks Consensus Estimate of $60.0 million. Product revenue, contributing 75.8% of Omnicell’s top line, increased 8.5% to $46.2 million in the quarter while revenues from Services and Others (contributing the rest), witnessed a marginal upside of 1.4%. The company operates in the niche automated medication distribution industry and stands to benefit from favorable demographic trends, regulatory environments, and the lack of nursing staff. As the information technology market is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/omcl-omnicell-analyst-maintains-neutral-on-shares/83310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell&#8217;s Electronic Health Record Wins Certification</title>
		<link>http://www.stockbloghub.com/2011/06/22/omcl-omnicells-electronic-health-record-wins-certification/77065</link>
		<comments>http://www.stockbloghub.com/2011/06/22/omcl-omnicells-electronic-health-record-wins-certification/77065#comments</comments>
		<pubDate>Wed, 22 Jun 2011 17:01:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77065</guid>
		<description><![CDATA[Omnicell, Inc. (OMCL), a leading developer and marketer of end-to-end automation solutions for the medication-use process, recently announced that its newly launched G4 platform received the ONC-ATCB certification as a Modular Electronic Health Record (“EHR&#8221;). Omnicell became the first hospital pharmacy automation company to achieve this certification and the company intends to support its clients to qualify for federal funding incentives under the American Recovery and Reinvestment Act (“ARRA”). The Centers for Medicare &#38; Medicaid Services, on May 19, 2011, made the first round of payments totaling $75 million to providers who successfully fulfilled the Stage One requirements for Meaningful Use.  The fulfillment of Meaningful Use criteria is essential for securing federal incentives. EHR automates the process of writing prescriptions and enables the physicians to send prescriptions directly to a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/omcl-omnicells-electronic-health-record-wins-certification/77065/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell  Earns Second Consecutive Best in Klas Award</title>
		<link>http://www.stockbloghub.com/2011/06/19/omcl-omnicell-earns-second-consecutive-best-in-klas-award/76681</link>
		<comments>http://www.stockbloghub.com/2011/06/19/omcl-omnicell-earns-second-consecutive-best-in-klas-award/76681#comments</comments>
		<pubDate>Sun, 19 Jun 2011 17:33:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76681</guid>
		<description><![CDATA[Omnicell (OMCL), recently announced that it has received recognition for its OmniRx automated dispensing system from leading research firm, KLAS for the second consecutive year.  Along with the  2011 “Best in KLAS&#8221; award for Automated Medication Dispensing Units for large hospitals with more than 200 beds category, Omnicell was also  recognized  as the Category Leader for OmniRx for hospitals under 200 beds. This is the sixth consecutive year that OmniRx has received this KLAS ranking as Category Leader. Omnicell, for the second consecutive year, was adjudged Category Leader for Pharmacy Automation: Medication Carousels for its WorkflowRx Carousel and Category Leader in the new Anesthesia Cabinets award category for Omnicell&#8217;s Anesthesia Workstation. Moreover, Omnicell&#8217;s OmniLinkRx received the Category Leader Distinction for Medication Order Management Systems in Klas’ Software &#38; Professional Services ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/omcl-omnicell-earns-second-consecutive-best-in-klas-award/76681/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Stock Review &#8211; May 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/05/11/mdt-medical-devices-stock-review-may-2010-industry-outlook/36750</link>
		<comments>http://www.stockbloghub.com/2010/05/11/mdt-medical-devices-stock-review-may-2010-industry-outlook/36750#comments</comments>
		<pubDate>Tue, 11 May 2010 21:55:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36750</guid>
		<description><![CDATA[The global medical devices industry is fairly large, with annual worldwide sales in 2009 in excess of $220 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different categories such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices, Healthcare IT, etc. We recommend companies providing life-sustaining products to investors in the medical devices space. These companies provide a strong recurring stream of revenues as patients are unable to forego these products due to their life-sustaining nature. Furthermore, investors should allocate funds to companies with high-earnings-quality profiles. Large companies with a wide portfolio of products are also better poised for improved returns. These companies have a greater capability of withstanding a downturn in the economy. We advise investors to avoid companies that have grown historically through ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/11/mdt-medical-devices-stock-review-may-2010-industry-outlook/36750/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2010/04/18/omcl-omnicell-incorporated-bull-of-the-day/34044</link>
		<comments>http://www.stockbloghub.com/2010/04/18/omcl-omnicell-incorporated-bull-of-the-day/34044#comments</comments>
		<pubDate>Mon, 19 Apr 2010 02:44:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34044</guid>
		<description><![CDATA[Hospital services like those provided by Omnicell, Inc. (OMCL) should exhibit strong growth over the long-term, benefiting from favorable demographic trends, regulatory environments and a lack of nursing staff. The market also remains underpenetrated. Moreover, the U.S. government&#8217;s approval of more than $20 billion in healthcare IT is likely to boost Omnicell&#8217;s top-line. A slowly recovering economy will also help the company going forward. Based on the company&#8217;s strong long-term outlook, we upgrade the stock to Outperform with a target price of $15.50. This is based on a P/S multiple of 2.2x our fiscal 2010 revenue estimate. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/18/omcl-omnicell-incorporated-bull-of-the-day/34044/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell Analyst Upgrades Shares</title>
		<link>http://www.stockbloghub.com/2010/04/09/omcl-omnicell-analyst-upgrades-shares/33298</link>
		<comments>http://www.stockbloghub.com/2010/04/09/omcl-omnicell-analyst-upgrades-shares/33298#comments</comments>
		<pubDate>Fri, 09 Apr 2010 21:41:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33298</guid>
		<description><![CDATA[We recently upgraded Omnicell, Inc. (OMCL) to an ‘Outperform’ with a target price of $15.50 based on a P/S of 2.2x our fiscal 2010 revenue estimate of $225 million. The company’s strong long-term outlook prompts us to upgrade the stock. Omnicell is a leading provider of systems and software solutions, primarily focusing on end-to-end automation solutions for the medication-use process. The U.S. government is increasingly emphasizing the use of healthcare IT these days. The U.S. government recently approved more than $20 billion in spending on healthcare IT. Though a majority of the spending will be felt between 2011 and 2015, this news is a major boost for Omnicell. Furthermore, an economic recovery round the corner will also help the company tap the under-penetrated healthcare IT market. However, Omnicell reported disappointing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/09/omcl-omnicell-analyst-upgrades-shares/33298/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell Analysts Maintain Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/03/10/omcl-omnicell-analysts-maintain-neutral-rating/30224</link>
		<comments>http://www.stockbloghub.com/2010/03/10/omcl-omnicell-analysts-maintain-neutral-rating/30224#comments</comments>
		<pubDate>Wed, 10 Mar 2010 20:16:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30224</guid>
		<description><![CDATA[We recently reiterated our Neutral rating on Omnicell, Inc. (OMCL) with a target price of $15.50. Omnicell reported disappointing results in the fourth quarter and fiscal 2009. In the fourth quarter, earnings per share were 2 cents, below the Zacks Consensus Estimate of 3 cents and the year-ago earnings of 10 cents. In fiscal 2009, earnings per share were a penny, compared to the Zacks Consensus Estimate of 2 cents and the year-ago earnings of 38 cents. Total revenues for the fourth quarter were $54.7 million, declining 11.9% year over year. Lower revenues can be attributed to lower demand for the company&#8217;s products due to the economic turbulence. Omnicell is a leading provider of systems and software solutions that develops end-to-end automation solutions for the medication-use process. Omnicell&#8217;s products are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/10/omcl-omnicell-analysts-maintain-neutral-rating/30224/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDRX) Medical Devices Stock Review &#8211; Feburary 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/02/01/mdrx-medical-devices-stock-review-feburary-2010-industry-outlook/26636</link>
		<comments>http://www.stockbloghub.com/2010/02/01/mdrx-medical-devices-stock-review-feburary-2010-industry-outlook/26636#comments</comments>
		<pubDate>Mon, 01 Feb 2010 22:23:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare Information Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[Hanger Orthopedic Group Inc.]]></category>
		<category><![CDATA[HGR]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26636</guid>
		<description><![CDATA[The global medical devices industry is fairly large, with annual worldwide sales in excess of $200 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different categories such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices, Healthcare IT, etc. We recommend companies providing life-sustaining products to investors in the medical devices space. These companies provide a strong recurring stream of revenues as patients are unable to forego these products due to their life-sustaining nature. Furthermore, investors should allocate funds to companies with high-earnings-quality profiles. Large companies with a wide portfolio of products are also better poised for improved returns. These companies have a greater capability of withstanding a downturn in the economy. Another area which is interestingly poised for growth these days is Healthcare IT. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/01/mdrx-medical-devices-stock-review-feburary-2010-industry-outlook/26636/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell Enters New Contract With Carolinas HealthCare System</title>
		<link>http://www.stockbloghub.com/2009/12/07/omcl-omnicell-enters-new-contract-with-carolinas-healthcare-system/22144</link>
		<comments>http://www.stockbloghub.com/2009/12/07/omcl-omnicell-enters-new-contract-with-carolinas-healthcare-system/22144#comments</comments>
		<pubDate>Mon, 07 Dec 2009 19:19:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22144</guid>
		<description><![CDATA[Omnicell, Inc. (OMCL) recently entered into a new contract with Carolinas HealthCare System (CHS) whereby the latter has selected Omnicell’s OmniRx automated medication dispensing cabinets (ADCs) to streamline management of medications in its hospitals. Carolinas HealthCare System is the largest healthcare system in the Carolinas and third largest non-profit public system in the U.S. Omnicell offers its customers frequent software upgrades to help them remain current with ever-changing regulatory issues as well as pharmacy and nursing best practices. Omnicell&#8217;s advanced automation solutions will help lower time and effort of CHS clinical staff for administrative processes. The advanced automation solutions enable clinical staff to monitor and control medication dispensing and reduce preventable medication errors. This helps the staff to focus more on patient care and improve clinical outcomes. While the value ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/07/omcl-omnicell-enters-new-contract-with-carolinas-healthcare-system/22144/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell Launches New Product</title>
		<link>http://www.stockbloghub.com/2009/11/25/omcl-omnicell-launches-new-product/21291</link>
		<comments>http://www.stockbloghub.com/2009/11/25/omcl-omnicell-launches-new-product/21291#comments</comments>
		<pubDate>Wed, 25 Nov 2009 18:34:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21291</guid>
		<description><![CDATA[Omnicell, Inc. (OMCL) recently launched a new product, Omnicell 14.0 with Anywhere RN, a software solution used in conjunction with Omnicell&#8217;s automated medication dispensing cabinets to ensure safe, efficient and accessible medication management throughout the hospital. South Jersey Healthcare Regional Medical Center has already implemented the new product for its hospital. Anywhere RN enables nurses to review medication orders from any hospital computer or workstation and select profiled medications for issue from an Omnicell automated dispensing cabinet. Nurses may also utilize the new product to record medication waste and queue return transactions. Anywhere RN is the industry’s first software solution to offer such facilities. Anywhere RN substantially increases the nurses&#8217; ability to access patient medications in a safer and more efficient manner. This is evident at South Jersey Healthcare Regional ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/25/omcl-omnicell-launches-new-product/21291/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OMCL) Omnicell Eclipses Consensus Estimate</title>
		<link>http://www.stockbloghub.com/2009/10/26/omcl-omnicell-eclipses-consensus-estimate/18687</link>
		<comments>http://www.stockbloghub.com/2009/10/26/omcl-omnicell-eclipses-consensus-estimate/18687#comments</comments>
		<pubDate>Mon, 26 Oct 2009 23:11:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Computer Based Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18687</guid>
		<description><![CDATA[Omnicell Inc. (OMCL) reported third quarter 2009 earnings per share of 10 cents yesterday, beating the Zacks Consensus Estimate of 2 cents. However, earnings per share came below the year-ago figure of 18 cents. Total revenues for the reported quarter were $54.0 million, declining 16.1% year over year. The decline can be attributed to lower demand for the company’s products due to the current economic turbulence. Omnicell is a leading provider of systems and software solutions that develops end-to-end automation solutions for the medication-use process. Omnicell’s products are primarily purchased by hospitals and nursing homes which are presently grappling with the current economic scenario of weak credit markets, rising expenses, higher unemployment, and erosion of wealth. This has ultimately resulted in a decline in net sales. Omnicell reported a contraction ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/26/omcl-omnicell-eclipses-consensus-estimate/18687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDRX) Medical Devices &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/10/16/mdrx-medical-devices-industry-outlook/17835</link>
		<comments>http://www.stockbloghub.com/2009/10/16/mdrx-medical-devices-industry-outlook/17835#comments</comments>
		<pubDate>Fri, 16 Oct 2009 20:38:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare Information Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Dickinson And Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[Hanger Orthopedic Group Inc.]]></category>
		<category><![CDATA[HGR]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merge Healthcare Incorporated.]]></category>
		<category><![CDATA[MRGE]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17835</guid>
		<description><![CDATA[The global medical devices industry is fairly large and is valued at roughly $223 billion, with the U.S. accounting for approximately 41%. The industry is divided into different categories such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices and Healthcare IT. In the medical devices space, we recommend that investors focus on companies providing life-sustaining products. These companies provide a strong recurring stream of revenues as patients are unable to forego these products. Furthermore, investors should allocate funds to companies with high-earnings-quality profiles. Large companies with a wide portfolio of products are also better poised for good returns. These companies are capable of withstanding the current economic recession. Another area which is interestingly poised for growth these days is Healthcare IT. The landscape has changed since the Obama Administration passed a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/mdrx-medical-devices-industry-outlook/17835/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Medical Devices &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/07/14/bax-medical-devices-industry-outlook/10016</link>
		<comments>http://www.stockbloghub.com/2009/07/14/bax-medical-devices-industry-outlook/10016#comments</comments>
		<pubDate>Wed, 15 Jul 2009 01:03:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson And Company]]></category>
		<category><![CDATA[Merge Healthcare Incorporated.]]></category>
		<category><![CDATA[MRGE]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=10016</guid>
		<description><![CDATA[Since the beginning of the global economic crisis, medical device stocks have fared slightly worse than the overall market, losing roughly 400 bps more than the S&#38;P500 (-31%) since September 1, 2008, on a market weighted basis. We continue to recommend that investors focus on companies providing life-sustaining products. We believe these products will remain insulated from the longer-term effects of the current economic crisis because target patients will be unable to forego procedures. The initial slide in the market left many strong companies looking very attractive. In the coming year, investors should allocate funds to companies with high earnings quality profiles. We recommend companies with the following characteristics: Size – (1) Larger companies will find it easier to survive any future liquidity issues and acquire new technologies at cents on the dollar.  ?(2) Size also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/14/bax-medical-devices-industry-outlook/10016/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

